KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Receivables - Net (2018 - 2025)

Historic Receivables - Net for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $44.8 million.

  • Adaptive Biotechnologies' Receivables - Net rose 981.77% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 981.77%. This contributed to the annual value of $41.7 million for FY2024, which is 990.81% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Receivables - Net stood at $44.8 million for Q3 2025, which was up 981.77% from $44.3 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Receivables - Net's 5-year high stood at $44.8 million during Q3 2025, with a 5-year trough of $14.2 million in Q2 2021.
  • Its 5-year average for Receivables - Net is $31.9 million, with a median of $31.5 million in 2023.
  • In the last 5 years, Adaptive Biotechnologies' Receivables - Net soared by 13009.36% in 2022 and then tumbled by 521.26% in 2023.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Receivables - Net stood at $17.4 million in 2021, then soared by 130.09% to $40.1 million in 2022, then decreased by 5.21% to $38.0 million in 2023, then increased by 9.91% to $41.7 million in 2024, then increased by 7.4% to $44.8 million in 2025.
  • Its last three reported values are $44.8 million in Q3 2025, $44.3 million for Q2 2025, and $43.6 million during Q1 2025.